Compare Moderna, Inc. (MRNA) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Banco Santander SA — how do they compare? Moderna, Inc. trades at $137.39 (market cap $56.02B), while Banco Santander SA trades at $14.79 (market cap $218.36B). The key difference: Banco Santander SA is far larger — about 3.9× Moderna, Inc.'s market cap, and Banco Santander SA pays a 1.87% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | SAN | |
|---|---|---|
Market Cap | $56.02B | $218.36B |
Sector | Health | Financials |
52-Week High | $174.38 | $15.05 |
52-Week Low | $22.36 | $9.65 |
Enterprise Value | $52.17B | — |
Dividend Yield | — | 1.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
Banco Santander (SAN) trades at $14.86, down 0.47% on the day, with a bullish technical signal from moving averages and a moderate buy consensus from analysts (64% buy ratings). The company reported record profitability in H1 2026 with a net income margin of 26.25% and recently completed the Webster acquisition to expand its U.S. presence, though cash flow trends show recent operational outflows.
SAN's outlook is supported by strong profitability and strategic expansion, but risks include volatile cash flows, high leverage with a debt-to-asset ratio of 17.8, and integration challenges from acquisitions. The stock offers value with a P/E of 14.47, but investors should weigh execution risks against growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
